Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Rinucumab Biologics Sequence Review Report 2026: PDGFRB Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rinucumab, an antibody targeting PDGFRB.
Latest Hotspot
8 min read
Refanezumab Biologics Sequence Review Report 2026: SIGLEC4 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Refanezumab, an antibody targeting SIGLEC4.
Latest Hotspot
8 min read
Opicinumab Biologics Sequence Review Report 2026: LINGO1 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Opicinumab, an antibody targeting LINGO1.
Latest Hotspot
8 min read
Muromonab Biologics Sequence Review Report 2026: CD3E Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Muromonab, an antibody targeting CD3E.
Latest Hotspot
8 min read
Mycobacterium abscessus infection Indication Strategy Report 2026: ATP synthase, Trials and Deals
30 July 2026
2026 Mycobacterium abscessus infection indication strategy covering epidemiology, ATP synthase biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Mycobacterium avium complex lung disease Indication Strategy Report 2026: ATP synthase, Trials and Deals
30 July 2026
2026 Mycobacterium avium complex lung disease indication strategy covering epidemiology, ATP synthase biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Pneumocystis jirovecii pneumonia Indication Strategy Report 2026: DHFR, Trials and Deals
30 July 2026
2026 Pneumocystis jirovecii pneumonia indication strategy covering epidemiology, DHFR biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Talaromycosis Indication Strategy Report 2026: CYP51, Trials and Deals
30 July 2026
2026 Talaromycosis indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Sporotrichosis Indication Strategy Report 2026: CYP51, Trials and Deals
30 July 2026
2026 Sporotrichosis indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Blastomycosis Indication Strategy Report 2026: CYP51, Trials and Deals
30 July 2026
2026 Blastomycosis indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Chronic pulmonary aspergillosis Indication Strategy Report 2026: CYP51, Trials and Deals
30 July 2026
2026 Chronic pulmonary aspergillosis indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Kartagener syndrome Indication Strategy Report 2026: CFTR, Trials and Deals
30 July 2026
2026 Kartagener syndrome indication strategy covering epidemiology, CFTR biology, active trials, transactions, unmet need, competition and market attractiveness.